GlassScriptPhysician profile
Jennifer Laessig
NPI 1225869274
$433.77
in general payments reported to CMS, 2019-2025
12 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Clinical Nurse Specialist provider received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $175 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $121.35 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $53.48 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $43.02 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $34.65 | 2025 | |
| Abbvie INC. | $32.98 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $29.19 | 2024 | Austedo Xr |
| Lilly USA, LLC | $24.70 | 2024 | Kisunla, Amyvid |
| Acadia Pharmaceuticals INC | $23.89 | 2025 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.53 | 2025 | |
| Supernus Pharmaceuticals, INC. | $19.30 | 2025 | Qelbree |
| Lundbeck LLC | $16.17 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Laessig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.